ALK and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), pembrolizumab has become a standard first-line therapy for patients with high PD-L1 expression (≥50%) and no EGFR or ALK mutations, demonstrating improved OS compared to chemotherapy alone.15 Similarly, in metastatic colorectal cancer (CRC), pembrolizumab is indicated for MSI-high or mismatch repair deficient (dMMR) tumors.